CelLBxHealth plc (CLBX) fair value: what the stock is really worth
We calculate from audited financials what CelLBxHealth plc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jun 25, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch CelLBxHealth plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 25, 2026.
How to read this chart
60‑month range £0.0085 – £1.56 · fair‑value band £0.0163 – £0.0271 · the £0.0085 price screens below the £0.0217 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 25, 2026.
Follow CelLBxHealth in your weekly email
Every Wednesday you see whether CelLBxHealth is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally.
Show more
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company also has a research collaboration with The Royal Marsden NHS Foundation Trust. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.
Stock analysis
CelLBxHealth plc (CLBX) currently trades at £0.0085, while our model-based Fair Value estimate is £0.0217, implying the stock looks roughly 60.8% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 87/100, which puts the evidence level at low.
Scenario range: £0.0163 (bear) to £0.0271 (bull), the price of £0.0085 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
CelLBxHealth plc reported revenue of £1.4M in FY2025 versus £1.0M in FY2021, a compound +7.5%/yr. Reported net income was −£19.5M in FY2025.
Key figures
Market cap 15.6M GBX · P/S ratio 5.95 · EPS (TTM) £−0.0600 · Return on equity −87.2% · Return on assets (EBIT) −67.6% · Operating margin −1,216% · Revenue (TTM) £2.6M · Revenue growth (YoY) −23.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 71% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 155%, CLBX screens cheaper than that median.
Fair Value models
Bear £0.0163Fair Value £0.0217Bull £0.0271
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.21/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−52.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,710.5% (2021) → −1,140.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 138 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside+155.3% · Top 25%
Profitability
Return on assets−40.0% · Bottom 25%
Growth and dividend
Revenue growth−23.0% · Bottom 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CelLBxHealth plc Fair Value". https://www.fairvalue-calculator.com/stock/CLBX
Frequently asked questions
Is CelLBxHealth plc (CLBX) overvalued or undervalued?
As of Jun 25, 2026, our model estimates a fair value of £0.0217 versus a price of £0.0085, about +155% upside (undervalued).
What is the fair value of CLBX?
Our model-based fair value for CelLBxHealth plc is £0.0217 (as of Jun 25, 2026), built from audited fundamentals. The current price: £0.0085.
What is the quality score of CLBX?
CelLBxHealth plc has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CelLBxHealth plc (CLBX)?
Our model-based price target is the fair value of £0.0217 (as of Jun 25, 2026) from 1 valuation models. Cautious scenario £0.0163, optimistic scenario £0.0271. It is a calculation from audited fundamentals, not an analyst target.
What is the CelLBxHealth plc stock forecast for 2026?
Our models put fair value at £0.0217, about +155% upside versus a price of £0.0085 (undervalued). Cautious scenario £0.0163, optimistic scenario £0.0271. The calculation is refreshed regularly with new filings.
What is the revenue of CelLBxHealth plc (CLBX)?
CelLBxHealth plc reported trailing-twelve-month revenue of about £2.6M (latest available figure, as of Jun 25, 2026).
What is the intrinsic value of CelLBxHealth plc (CLBX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CelLBxHealth plc it is £0.0217 per share (as of Jun 25, 2026), against a price of £0.0085. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is CelLBxHealth plc stock overvalued or undervalued in 2026?
As of Jun 25, 2026, CLBX trades below its calculated fair value: price £0.0085, fair value £0.0217, a gap of about +155% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLBX?
No. The price is what the market pays today (£0.0085); the fair value is what the company's own numbers justify (£0.0217). For CelLBxHealth plc the two are £0.0132 per share apart. That gap is exactly why we show both numbers side by side.
How much is CelLBxHealth plc worth?
The market values CelLBxHealth plc at about 15.6M GBX (market capitalisation, as of Jun 25, 2026). Per share that is £0.0085; our models calculate a fair value of £0.0217 per share.
What do the bullish and bearish scenarios say about CLBX?
Our models span a range for CelLBxHealth plc: cautious scenario £0.0163, base £0.0217, optimistic £0.0271 per share (as of Jun 25, 2026, price £0.0085). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CelLBxHealth plc (CLBX)?
Balance-sheet figures for CelLBxHealth plc (as of Jun 25, 2026): return on equity −87.2%. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is CLBX from its 52-week high?
CelLBxHealth plc trades at £0.0085, about 71% below its 52-week high of £0.0295 and at the low of £0.0085 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0217 is for.
Which stocks are comparable to CelLBxHealth plc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CelLBxHealth plc stock attractive at the current price?
The data as of Jun 25, 2026: price £0.0085, calculated fair value £0.0217 (+155%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLBX calculated?
We run CelLBxHealth plc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.0217, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. CelLBxHealth plc currently trades 61 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CelLBxHealth plc (CLBX)?
The closing price on Sep 30, 2026 was £0.0085. Our model-based fair value is £0.0217, about +155% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CelLBxHealth plc right now?
The large discount to fair value meets weak quality (23/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (£0.0163). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of CelLBxHealth plc
How large is the market capitalisation of CelLBxHealth plc (CLBX)?
The market capitalisation of CelLBxHealth plc is 15.6M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CelLBxHealth plc (CLBX)?
The price-to-sales ratio of CelLBxHealth plc is 5.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CelLBxHealth plc (CLBX)?
Earnings per share at CelLBxHealth plc are £−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CelLBxHealth plc (CLBX)?
The return on equity (ROE) of CelLBxHealth plc is −87.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CelLBxHealth plc (CLBX)?
On an EBIT basis the return on assets of CelLBxHealth plc is −67.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CelLBxHealth plc (CLBX)?
The operating margin of CelLBxHealth plc is −1,216% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CelLBxHealth plc (CLBX)?
Revenue at CelLBxHealth plc is growing −23.0% versus a year earlier (3y avg +9.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CelLBxHealth plc (CLBX) generate?
The free cash flow of CelLBxHealth plc is −9.5M GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch CelLBxHealth plc in the live analysis
One click puts CelLBxHealth plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jun 25, 2026